Isolation, structural identification, synthesis, and pharmacological profiling of 1,2-trans-dihydro-1,2-diol metabolites of the utrophin modulator ezutromid
5-(Ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole (ezutromid, 1) is a first-in-class utrophin modulator that has been evaluated in a phase 2 clinical study for the treatment of Duchenne muscular dystrophy (DMD). Ezutromid was found to undergo hepatic oxidation of its 2-naphthyl substituent to pro...
Main Authors: | Chatzopoulou, M, Claridge, T, Davies, K, Davies, S, Elsey, D, Emer, E, Fletcher, A, Harriman, S, Robinson, N, Rowley, J, Russell, A, Tinsley, J, Weaver, R, Wilkinson, I, Willis, N, Wilson, F, Wynne, G |
---|---|
Format: | Journal article |
Language: | English |
Published: |
American Chemical Society
2019
|
Similar Items
-
Chemical proteomics and phenotypic profiling identifies the aryl hydrocarbon receptor as a molecular target of the utrophin modulator ezutromid
by: Wilkinson, IVL, et al.
Published: (2019) -
Oxidative functionalisation of SuperQuat enamides: Asymmetric synthesis of homochiral 1,2 diols
by: Davies, S, et al.
Published: (2003) -
Mechanism of action studies of the utrophin modulator ezutromid for the treatment of Duchenne muscular dystrophy
by: Wilkinson, I
Published: (2019) -
Ammonium-directed dihydroxylation: metal-free synthesis of the diastereoisomers of 3-aminocyclohexane-1,2-diol.
by: Aciro, C, et al.
Published: (2008) -
A phase 1b trial to assess the pharmacokinetics of ezutromid in pediatric duchenne muscular dystrophy patients on a balanced diet
by: Muntoni, F, et al.
Published: (2019)